A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors
Conditions: Relapsed or Refractory Lymphomas; Advanced Solid Tumor

Interventions: Drug: LP-284

Sponsors: Lantern Pharma Inc.

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 17, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments